Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults

Phase 4

Completed

Conditions: Obesity

Interventions: Drug: Orlistat

First Posted Date: 2016-03-11

Last Posted Date: 2016-04-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT02706067

A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

Phase 2

Completed

Conditions: Sjogren's Syndrome

Interventions: Drug: RO5459072
Drug: Placebo

First Posted Date: 2016-03-08

Last Posted Date: 2018-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 75

Registration Number: NCT02701985

Locations: 🇺🇸
Shanahan Rheumatology & Immunology, PLLC, Raleigh, North Carolina, United States
🇺🇸
Wallace Rheumatic Study Center, Beverly Hills, California, United States
🇺🇸
Winthrop University Hospital, Mineola, New York, United States

and more 28 locations

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Ranibizumab
Drug: Faricimab

First Posted Date: 2016-03-04

Last Posted Date: 2020-09-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 229

Registration Number: NCT02699450

Locations: 🇺🇸
United Med Res Inst, Inglewood, California, United States
🇺🇸
Ophthalmic Clinical Trials San Diego, Oceanside, California, United States
🇺🇸
Southern CA Desert Retina Cons, Palm Desert, California, United States

and more 56 locations

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: RO6889450

First Posted Date: 2016-03-04

Last Posted Date: 2017-11-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 164

Registration Number: NCT02699372

Locations: 🇳🇱
PRA Health Sciences Early Development Services, Zuidlaren, Netherlands

Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Rituximab

First Posted Date: 2016-03-04

Last Posted Date: 2016-10-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 130

Registration Number: NCT02699892

Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Pirfenidone

First Posted Date: 2016-03-04

Last Posted Date: 2017-04-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1009

Registration Number: NCT02699879

Locations: 🇦🇹
Medizinische Universitat Innsbruck; Department of Internal Medicine, Pneumology Centre, Innsbruck, Austria
🇩🇰
Aarhus University Hospital; Lungemed afd. B, Aarhus, Denmark
🇦🇹
LKH Hohenems; Abteilung für Pulmologie, Hohenems, Austria

and more 103 locations

A Study of Prevalence of EGFR Mutations in Participants With NSCLC

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2016-03-01

Last Posted Date: 2016-07-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 69

Registration Number: NCT02695849

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Erlotinib
Drug: Gemcitabine

First Posted Date: 2016-02-29

Last Posted Date: 2017-03-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT02694536

A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2016-02-29

Last Posted Date: 2017-01-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT02694718

A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Methotrexate
Drug: Cyclophosphamide
Other: Placebo Cyclophosphamide
Other: Placebo Methotrexate
Other: Placebo Rituximab
Drug: Rituximab

First Posted Date: 2016-02-26

Last Posted Date: 2016-11-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 161

Registration Number: NCT02693210

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy